Suppr超能文献

肝细胞癌的肝移植:一种纳入移植前炎症细胞因子的预后模型。

Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines.

作者信息

Sun Ruiqi, Zhang Liang, Yang Zhentao, Zhou Ke, Tang Hong, Zhao Wentao, Wang Ning, Yu Xiaobo, Huang Yiqian, Xie Haiyang, Zheng Shusen, Zhang Wu

机构信息

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou 310003, Zhejiang, China.

Department of Pharmacy, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.

出版信息

Cytokine. 2022 May;153:155847. doi: 10.1016/j.cyto.2022.155847. Epub 2022 Mar 15.

Abstract

PURPOSE

Liver transplantation (LT) remains an optimal treatment for selected hepatocellular carcinoma (HCC). Cytokines can be obtained by minimally invasive techniques and are associated with the development of HCC. The purpose of our investigation was to explore the prognostic value of pretransplant serum inflammatory cytokine profiles in HCC patients for LT.

METHODS

We detected forty inflammatory cytokines in pre-LT serum from 42 HCC patients by using an inflammation-related antibody array. A pretransplant serum inflammatory cytokine-associated risk assessment model (pre-SCRAM) was developed and was validated in an external cohort of 213 HCC patients who underwent LT and were then followed prospectively.

RESULTS

The pre-LT factors independently associated with recurrence-free survival (RFS) were as follows: B-lymphocyte chemoattractant (BLC), interleukin (IL)-12p40 and maximum tumor diameter. High IL-12P40 level was associated with a significantly smaller maximum tumor diameter (p = 0.021), decreased proportion of nodules ≥ 3 (p = 0.001), lower platelet counts (p = 0.011) and lower portal vein tumor thrombus (p = 0.031). Conversely, recipients with poor BLC level had higher alpha-fetoprotein (AFP) levels (p = 0.016). Kaplan-Meier analyses revealed that high pre-LT BLC or IL-12p40 level was associated with superior RFS. The pre-SCRAM stratified recipients into three risk groups: high risk, intermediate risk and low risk. In the validation cohort, for patients in the high, intermediate, and low risk groups, the 3-year RFS rates were 29.3%, 58.7%, and 82.2%, respectively, the 3-year HCC-specific survival rates were 54.5%, 73.8%, and 86%, respectively, and the 3-year overall survival rates were 44.4%, 60.9%, and 79.9%, respectively. The pre-SCRAM model performed well and remained significant in optimizing the risk stratification of recurrence in patients beyond the Milan criteria or the AFP model.

CONCLUSION

Pretransplant cytokine profiles can provide powerful prognostic information in the setting of LT for HCC. A pre-LT risk model incorporating cytokines showed excellent efficiency in recurrence prediction for HCC patients, which could ultimately stratify the prognosis in patients beyond the Milan criteria or the AFP model.

摘要

目的

肝移植(LT)仍是某些肝细胞癌(HCC)的最佳治疗方法。细胞因子可通过微创技术获得,且与HCC的发生发展相关。我们研究的目的是探讨肝移植前血清炎症细胞因子谱对HCC患者肝移植的预后价值。

方法

我们使用炎症相关抗体芯片检测了42例HCC患者肝移植前血清中的40种炎症细胞因子。建立了肝移植前血清炎症细胞因子相关风险评估模型(pre-SCRAM),并在213例接受肝移植并进行前瞻性随访的HCC患者外部队列中进行了验证。

结果

与无复发生存期(RFS)独立相关的肝移植前因素如下:B淋巴细胞趋化因子(BLC)、白细胞介素(IL)-12p40和最大肿瘤直径。高IL-12P40水平与显著更小的最大肿瘤直径相关(p = 0.021),≥3cm结节比例降低(p = 0.001),血小板计数降低(p = 0.011)和门静脉肿瘤血栓减少(p = 0.031)。相反,BLC水平低的受者甲胎蛋白(AFP)水平较高(p = 0.016)。Kaplan-Meier分析显示,肝移植前高BLC或IL-12p40水平与更好的RFS相关。pre-SCRAM将受者分为三个风险组:高风险、中风险和低风险。在验证队列中,高、中、低风险组患者的3年RFS率分别为29.3%、58.7%和82.2%,3年HCC特异性生存率分别为54.5%、73.8%和86%,3年总生存率分别为44.4%、60.9%和79.9%。pre-SCRAM模型表现良好,在优化米兰标准或AFP模型以外患者的复发风险分层方面仍然具有显著意义。

结论

肝移植前细胞因子谱可为HCC肝移植患者提供有力的预后信息。纳入细胞因子的肝移植前风险模型在预测HCC患者复发方面显示出优异的效率,最终可对米兰标准或AFP模型以外患者的预后进行分层。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验